Expert Interview
Discussing the approval of DexCom's new G7 15 Day CGM System for Type 1 and Type 2 Diabetes
Ticker(s): DXCM, SENS, ABT, MDTInstitution: Columbia University
- Associate Professor of Endocrinology at Columbia University.
- Manages 800 patients with diabetes and 280 patients who are on insulin pumps.
- Research focuses on the role of developmental pathways in the regulation of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease and the use of existing therapeutic agents in other scientific areas in novel applications to ameliorate obesity-induced complications including cancer.
Please describe your background and patient setting
Added By: ben_adminHow many patients do you manage who utilize a CGM device?
Added By: ben_adminWhat are the most popular CGM devices used today?
Added By: ben_adminWhat is your opinion of the Dexcom G7 15 Day?
Added By: ben_adminCan you provide an overview of the different CGMs available on the market for patients? What are the differences between these CGMs?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
